Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788090 | PMC |
http://dx.doi.org/10.1001/jama.2015.10347 | DOI Listing |
Sex Transm Infect
December 2024
Centre for the Aids Programme of Research in South Africa, Durban, South Africa
Eur J Clin Microbiol Infect Dis
November 2024
GSK, Rockville, MD, USA.
Purpose: To describe the relationships between Neisseria meningitidis (NM) and Neisseria gonorrhoeae (NG) at genetic, population, and individual levels; to review historical trends in antimicrobial resistance (AMR); to review the treatment and preventive landscapes and explore their potential impact on AMR.
Methods: A narrative literature search was conducted in PubMed, with searches restricted to 2003-2023 and additional articles included based on expertise.
Results: NM and NG are closely related bacterial pathogens causing invasive meningococcal disease (IMD) and gonorrhea, respectively.
Vaccines (Basel)
November 2024
Guangdong Provincial Institute of Public Health, Guangzhou 511430, China.
: Serosurveillance of epidemic cerebrospinal meningitis (ECM) in healthy individuals is crucial for assessing disease risk and evaluating the effectiveness of vaccinations. However, this practical work is rare in China. : We conducted cross-section serosurveillance in Guangzhou, Zhanjiang, and Heyuan in Guangdong Province, measuring Anti-Nm IgG with serogroups A, C, Y, and W, and analyzed the trends using a generalized additive model (GAM).
View Article and Find Full Text PDFAm J Med
November 2024
Infectious Disease Unit, Department of Medicine, University of Udine, Udine, Italy.
Background: Coagulation plays a crucial role in innate immune response to invasive infections. Coagulative biomarkers might predict clinical outcomes differently, depending on etiology.
Methods: A retrospective study was conducted during a 79-month period, recruiting 90 patients with meningitis or bloodstream infection caused by Neisseria meningitidis (n = 47) or Streptococcus pneumoniae (n = 43), median age 19 and 58 years, respectively.
Vaccine
January 2025
Pfizer R&D UK Limited, Orega, Marlow International, Parkway, Marlow, SL7 1YL, UK,. Electronic address:
Background: Vaccination against 5 prominent meningococcal serogroups (A/B/C/W/Y) is necessary for broad disease protection. We report immunopersistence through 4 years after a 2-dose (6-month interval) pentavalent MenABCWY primary vaccine series and safety and immunogenicity of a booster administered 4 years after primary vaccination.
Methods: This randomized, active-controlled, observer-blinded study was conducted in the United States and Europe.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!